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Immunotherapies targeting the immune checkpoint
receptors have shown great promise for a subset of can-
cer patients. However, robust and safe combination
therapies are still needed to increase the benefit of can-
cer immunotherapy and bring it to broader patient
populations. We have recently shown that E7046, a spe-
cific EP4 antagonist, possesses significant anti-tumor
growth activity in multiple preclinical tumor models
through modulating myeloid cells including tumor asso-
ciated macrophages (TAMs) and myeloid-derived sup-
pressor cells (MDSCs) (AACR 2015, poster #275). Here
we evaluated the anti-tumor activities of E7046 in com-
bination with the checkpoint inhibitors anti-CTLA4 and
anti-PD1 antibodies, and also with E7777, a recombinant
IL-2/diphtheria toxin fusion protein, in immunogenic
CT26 and poorly immunogenic 4T1 tumor models. In
the CT26 model, concomitant treatment of E7046 and
anti-PD1 led to pronounced tumor growth inhibition,
with 40% of the mice rendered stably tumor free, while
either single agent produced mostly tumor growth inhi-
bitory activity and only an occasional tumor-free animal.
In the same model, markedly improved anti-tumor
activity was observed for the combination of E7046 and
E7777, with up to 20% of animals rendered stably tumor
free, compared with only modest anti-tumor activity of
either single agent treatment alone. In the 4T1 model,
combining E7046 and anti-CTLA4 resulted in a nearly
complete tumor growth inhibition; either agent alone
had only modest growth inhibitory activity. In the
tumor microenvironment of both models, an effective
anti-tumor immune response was induced by the com-
bination treatments including E7046 as indicated by the
robust accumulation and activation of CD8 cytotoxic
T cells (CTL) and/or significantly improved ratio of acti-
vated GZMB+CD8+ CTL vs CD4+CD25+Foxp3+ Treg
cells. In addition, combination treatments including
E7046 in tumor-bearing mice showed no additional
gross toxicity compared with immune checkpoint inhibi-
tors alone or E7777 alone. Taken together, these results
demonstrated a superior activity of combinational thera-
pies including E7046 over immune checkpoint inhibitors
or E7777 alone with acceptable toxicity in preclinical
models, and therefore candidates for combination trials
in patients. IND filing number of E7046 is 125272.
Published: 4 November 2015
doi:10.1186/2051-1426-3-S2-P350
Cite this article as: Bao et al.: Combination of EP4 antagonist and
checkpoint inhibitors promotes anti-tumor effector T cells in preclinical
tumor models. Journal for ImmunoTherapy of Cancer 2015 3(Suppl 2):P350.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Eisai Inc., Andover, MA, USA
Bao et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P350
http://www.immunotherapyofcancer.org/content/3/S2/P350
© 2015 Bao et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
